CBER’s Long Goodbye: Biologics Approval Time Jumps To 30 Months In 2002
Executive Summary
The average approval time for new biologic therapeutics and vaccines in 2002 was 30.1 months, an 11-month increase from 2001
You may also be interested in...
Pfizer Could Launch Three Significant NMEs in 2004; Will Any Surpass Viagra?
Pfizer's product outlook is brightening in 2004, with the launch of three commercially significant new molecular entity products on the horizon
Pfizer Could Launch Three Significant NMEs in 2004; Will Any Surpass Viagra?
Pfizer's product outlook is brightening in 2004, with the launch of three commercially significant new molecular entity products on the horizon
Baxter/Alpha Aralast Launch Will Ease Bayer Prolastin Supply Pressure
Baxter/Alpha Therapeutics' Aralast alpha-1 proteinase inhibitor launch should ease ongoing supply pressures on Bayer's Prolastin